<DOC>
	<DOCNO>NCT01609049</DOCNO>
	<brief_summary>This prospective observational study evaluate efficacy safety Pegasys ( peginterferon alfa-2a ) combination ribavirin patient chronic hepatitis C , include patient compensate liver cirrhosis , clinical practice . Data collect patient receive Pegasys ribavirin 72 week treatment ( accord register indication depend baseline viral load , genotype virological response ) 24-week follow-up .</brief_summary>
	<brief_title>An Observational Study Pegasys ( Peginterferon Alfa-2a ) Combination With Ribavirin Patients With Chronic Hepatitis C Compensated Liver Cirrhosis ( STANDART )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Adult patient , &gt; /= 18 year age Serologically confirm Chronic hepatitis C , HCV RNA detectable Compensated liver cirrhosis ( ChildPugh Class A ) include Initiating combine therapy Pegasys ribavirin HIV coinfection Contraindications combine therapy accord actual prescribing information</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>